Does the Greater Bay Area (GBA) Connect / Macau Fast-Track Channel Create US MFN Price Exposure?

The question, and why it matters now

Short answer: no. Selling a product into the mainland through the Greater Bay Area’s urgent-import route does not expose your US price under the Most-Favored-Nation (MFN) policy. But the question is worth answering carefully, because the instinct behind it is sound.

Since 2025, the US has pursued MFN pricing in earnest — an executive order in May 2025, followed by HHS guidance defining a target price benchmarked to peer countries and a CMS demonstration model. The logic of any reference-pricing scheme is that a low price recorded in one market can pull down the price in another. So manufacturers using low-volume access channels abroad reasonably ask whether a price booked in a Chinese hospital could resurface in Washington. For this channel, the answer is no — and the reasons are structural, not a matter of interpretation.

What the GBA urgent-import channel actually is

The channel originates in a central-government measure: in November 2020 the National Medical Products Administration issued a work plan allowing designated healthcare institutions in the mainland Greater Bay Area to use drugs registered in Hong Kong or Macao — the latter including products routed through Macau’s fast-track pathway — and medical devices already used in those regions’ public hospitals, where there is an urgent clinical need. It was first implemented at the University of Hong Kong–Shenzhen Hospital on a trial basis, then extended gradually to other qualifying institutions across the region.

The mechanics are deliberately narrow. A product must already be approved in Hong Kong or Macao but not yet on the mainland, and a designated hospital must demonstrate genuine urgent clinical need; the Guangdong authority then approves a batch import for that institution. Because the products are not on China’s national reimbursement lists, patients typically pay out of pocket. Real-world evidence generated at these sites can later support a national registration filing. In 2024 the framework was upgraded from interim provisions to formal provincial legislation: the Guangdong Provincial People’s Congress adopted regulations governing these imports on 31 July 2024, effective 1 December 2024.

How US MFN reference pricing actually works

To see why, you have to look at how MFN pricing is built. The policy compares a US price not against the whole world, but against a defined basket of reference markets — and the composition of that basket is what determines exposure.

Two definitions are in play. In May 2025, HHS set out the broad version: the MFN target is the lowest price for a drug in an OECD member country whose GDP per capita is at least 60% of the United States’. In November 2025, CMS operationalised a narrower one through its voluntary GENEROUS model for Medicaid, which benchmarks against the second-lowest manufacturer-reported net price across just eight countries — the United Kingdom, France, Germany, Italy, Canada, Japan, Switzerland and Denmark — adjusted for GDP per capita.

The two differ in breadth, but they share a defining feature: every eligible country is a wealthy OECD member. That is not incidental. MFN exists to stop the US paying more than its comparable high-income peers, so the reference set is drawn from that peer group by construction. A price from outside it has no slot in the formula.

Why the GBA channel sits outside it

Apply that to the Greater Bay Area channel and the conclusion is immediate, for two independent reasons.

First, and decisively: China, Hong Kong and Macao are not OECD members. The OECD has 38 member countries, and none of the three is among them. Because every version of the MFN reference basket is drawn exclusively from OECD members — the broad HHS definition — or from a hand-picked subset of them — the GENEROUS eight — a price recorded in a Guangdong hospital has no place in the calculation. It is not a low number that drags the benchmark down; it is a number the benchmark never looks at. That holds regardless of how small the price is or how the sale is structured.

Second, and independently: the channel does not generate the kind of price MFN references in the first place. MFN benchmarks against reported net prices in national markets — the figures payers and manufacturers transact at system-wide. GBA sales are confidential, hospital-by-hospital supply contracts for self-pay patients, with no published national tariff of the sort NRDL negotiation produces. Even in a hypothetical world where China were a reference country, there would be no public, system-level price to cite.

Either reason is sufficient alone. Together they place the channel comfortably outside the reach of US MFN pricing — not by interpretation, but by the structure of the policy.

A caveat for the largest manufacturers

The first concerns manufacturers who have struck their own deals. Beyond the general models, the administration has reached voluntary MFN pricing agreements with 17 of the largest manufacturers — covering roughly 86% of the US branded market by April 2026 — and is working with Congress to codify them. These bespoke agreements can extend MFN pricing across commercial, Medicare, Medicaid and cash channels, well beyond the Medicaid-only GENEROUS model. If your company is party to one, the operative reference basket is whatever that contract defines, not the public formula — so read your own terms. That said, every publicly described version, bespoke deals included, benchmarks against developed-nation prices; none reaches into China.

The second is about scope, not risk. This piece answers one question — whether the GBA channel creates US MFN price exposure — and the answer is no. That is separate from the channel’s commercial profile, which turns on product-specific and regulatory factors that have no bearing on MFN. And because US drug-pricing policy is still developing, the analysis reflects the framework as of mid-2026: the structural conclusion — China sits outside every MFN reference basket — is durable, while the surrounding specifics will continue to move.

No Exposure, by Design

Strip away the detail and one fact decides it: the Most-Favored-Nation policy can only reference prices from a closed club of wealthy OECD economies, and China, Hong Kong and Macao are not in it. A price booked in a Guangdong hospital is not a low benchmark — it is invisible to the benchmark entirely. Layer on the channel’s confidential, self-pay pricing and the exposure is not merely small; it is structurally absent. The largest manufacturers carrying bespoke federal agreements should still check their own terms. Everyone else can treat the question as closed.

A note on currency: US Most-Favored-Nation (MFN) drug-pricing policy is evolving rapidly. As of mid-June 2026, the administration has concluded voluntary MFN agreements with 17 of the largest manufacturers, has signaled it will pursue legislation to codify them, and operates one active model — the voluntary GENEROUS model for Medicaid. Two further models for Medicare — GLOBE, for Part B, and GUARD, for Part D — have been proposed but not yet finalized. Importantly for the analysis above, none of these instruments, nor the underlying HHS benchmark or any announced manufacturer agreement, uses China, Hong Kong or Macao as a reference market: every version draws its comparator prices from developed OECD economies. Because new executive actions, rulemakings and agreements continue to emerge, this article reflects the policy framework as of mid-June 2026 only, and the specific programs and figures cited may subsequently change. Readers should confirm the current rules before relying on them.